Update on Letter to Chief Justice of India by Campaign for Affordable Trastuzumab

Subsequent to the letter to Chief Justice of India by Campaign for Affordable Trastuzumab stating concerns regarding IP Owners Association (IPOA) with India judiciary ,  we have heard from the credible sources that IPOA’s meeting with IPAB and Delhi High Court have been summarily cancelled.

 

Posted in Campaign for Affordable Trastuzumab, Conflict of Interest | Leave a comment

Campaign for Affordable Trastuzumab writes to Chief Justice of India raising concerns on scheduled meeting of IPAB, Delhi High Court with IP Owners Associations

Campaign for Affordable Trastuzumab wrote to Chief Justice of India raising concern about  “Innovation Dialog” being organised in India from November 16-22, 2014 by the Intellectual Property Owners Association (IPOA). The campaign specifically mentioned about IPOA’s proposed meetings with representatives of the IPAB, the Delhi High Court and the Patent Controller’s offices, as these institutions are in the process of hearing patent-related cases that could involve IPOA members and questioned  the ethics and propriety of meetings and interactions between the judiciary and the IPOA delegation.

 

The letter sent by Campaign for Affordable Trastuzumab can be accessed here

To view the agenda of IPOA meeting, click here.

Posted in Campaign for Affordable Trastuzumab, Conflict of Interest, Injunctions, IP Rights, IPR Enforcement, IPR infringement | Leave a comment

CII-DIPP-IPO Conference on IP Law & Enforcement ignores Public Interest

Department of Industrial Policy & Promotion (DIPP), Ministry of Commerce, India along with Confederation of Indian Industries and Intellectual Property India (IPO) is holding an international conference on “IP Law and Enforcement”  in Noida, 20-21 Nov 2014. Access the agenda of the conference here.

This conference raises concerns on IP and public interest as well as a Government of India’s established stand of balanced approach to intellectual protection and enforcement. Government of India in all international and domestic forum has always taken a firm stand to balance the IP protection and enforcement, a private interest with the public interest i.e. access to medicines, access to knowledge, access to technology etc. The conference is a clear departure from this stand and the agenda is completely IP Maximalist. The agenda seem to accommodate only corporations and law firms and have excluded academia and civil society organisations.

Continue reading

Posted in Conflict of Interest, IP Rights, IPR Enforcement | Leave a comment

New development in the COPD drug Indaceterol

The patented COPD drug Indaceterol is imported by Novartis and sold under an agreement by Lupin at a price of Rs. 677 for a unit of ten capsules whereas Cipla’s in October 2014 launched at risk the generic version at Rs.130 for a unit of 10 capsules. 

Cipla’s petition to the Department of Industrial Policy & Promotion (DIPP) to revoke the Novartis patents on Indaceterol is available hereContinue reading

Posted in access to medicines, Drug Pricing, Revocation | Tagged , , | Leave a comment

Trading away democracy. How CETA’s investor protection rules threaten the public good in Canada and the EU

Source: Corporate Europe Observatory

November 19th,2014

The first in-depth analysis of the investment provisions of the Canadian-EU free trade agreement (CETA) has found that both the EU and Canada will be exposing themselves to greater future government policy constrain, and lengthy and expensive legal battles.
 
The report published today by 15 environmental NGOs, citizens’ groups and workers unions from both sides of the Atlantic called Trading Away Democracy can been downloaded in English, French and German. Executive summaries can be found in English, German, French, Spanish, Dutch, Danish, Finnish, Greek, Bulgarian, Czech, Polish and Estonian. Continue reading

Posted in FTAs, investor state dispute | Tagged | Leave a comment

Corruption tars drug industry drive to improve access for poor; GlaxoSmithKline retains top spot

Source: Economic Times

November 17,2014

LONDON: The world’s top drugmakers have improved access to medicines in developing countries, according to a report on Monday, but their good work is undermined by a sorry record of unethical behaviour.

The Access to Medicines Index, which ranks the 20 leading pharmaceutical companies every two years on how well they get treatments to the poor, said the industry’s progress had been “uneven”. Continue reading

Posted in access to medicines, patent | Tagged , , , | Leave a comment

Another big fat lie on R&D Cost for developing a new drug

The Tufts Center for the Study of Drug Development, non profit group
has released a study giving R&D cost of $ 2.558 million for developing
a new drug.Read their press release below.

While they claim to be independent academic organisation, their study
seem to very much in line with Big Pharma’s lies about billions being
spent on R&D. Also see here Tufts Corporate
Sponsorship that reflects their proximity to corporate. Continue reading

Posted in access to medicines, Drug Pricing, R&D | Leave a comment

Corruption tars drug industry drive to improve access for poor

Source: Reuters

November 16,2014

 The world’s top drugmakers have improved access to medicines in developing countries, according to a report on Monday, but their good work is undermined by a sorry record of unethical behavior.

The Access to Medicines Index, which ranks the 20 leading pharmaceutical companies every two years on how well they get treatments to the poor, said the industry’s progress had been “uneven”. Continue reading

Posted in access to medicines | Tagged , , , , , | Leave a comment

R&D cost estimates – MSF response to Tufts CSDD study on cost to develop a new drug

Source: MSF Access Campaign

November 18,2014

Quote:

“The pharmaceutical industry-supported Tufts Center for the Study of Drug Development claims it costs US$2.56 billion to develop a new drug today; but if you believe that, you probably also believe the earth is flat.

“GlaxoSmithKline’s CEO Andrew Witty himself says the figure of a billion dollars to develop a drug is a myth; this is used by the industry to justify exorbitant prices. We need to ask ourselves, if the CEO of a top pharmaceutical company says it’s a myth that it costs a billion dollars to develop a drug, can we really take this new figure 2.56 billion seriously? Continue reading

Posted in access to medicines, Drug Pricing, R&D | Leave a comment